|
1
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al: Global Burden of Disease Cancer Collaboration: The
global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hollier BG, Evans K and Mani SA: The
epithelial-to-mesenchymal transition and cancer stem cells: A
coalition against cancer therapies. J Mammary Gland Biol Neoplasia.
14:29–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryu HS, Park DJ, Kim HH, Kim WH and Lee
HS: Combination of epithelial-mesenchymal transition and cancer
stem cell-like phenotypes has independent prognostic value in
gastric cancer. Hum Pathol. 43:520–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bezdekova M, Brychtova S, Sedlakova E,
Langova K, Brychta T and Belej K: Analysis of Snail-1, E-cadherin
and claudin-1 expression in colorectal adenomas and carcinomas. Int
J Mol Sci. 13:1632–1643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitselou A, Galani V, Skoufi U, Arvanitis
DL, Lampri E and Ioachim E: Syndecan-1, epithelial-mesenchymal
transition markers (E-cadherin/beta-catenin) and
neoangiogenesis-related proteins (PCAM-1 and Endoglin) in
colorectal cancer. Anticancer Res. 36:2271–2280. 2016.PubMed/NCBI
|
|
7
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and De García Herreros A: The transcription
factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geiger TR and Peeper DS: Metastasis
mechanisms. Biochim Biophys Acta. 1796:293–308. 2009.PubMed/NCBI
|
|
9
|
Findlay VJ, Wang C, Watson DK and Camp ER:
Epithelial-to-mesenchymal transition and the cancer stem cell
phenotype: Insights from cancer biology with therapeutic
implications for colorectal cancer. Cancer Gene Ther. 21:181–187.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
11
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shioiri M, Shida T, Koda K, Oda K, Seike
K, Nishimura M, Takano S and Miyazaki M: Slug expression is an
independent prognostic parameter for poor survival in colorectal
carcinoma patients. Br J Cancer. 94:1816–1822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kroepil F, Fluegen G, Vallböhmer D, Baldus
SE, Dizdar L, Raffel AM, Hafner D, Stoecklein NH and Knoefel WT:
Snail1 expression in colorectal cancer and its correlation with
clinical and pathological parameters. BMC Cancer. 13:1452013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ngan CY, Yamamoto H, Seshimo I, Ezumi K,
Terayama M, Hemmi H, Takemasa I, Ikeda M, Sekimoto M and Monden M:
A multivariate analysis of adhesion molecules expression in
assessment of colorectal cancer. J Surg Oncol. 95:652–662. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gagliardi G, Kandemir O, Liu D, Guida M,
Benvestito S, Ruers TG, Benjamin IS, Northover JM, Stamp GW, Talbot
IC, et al: Changes in E-cadherin immunoreactivity in the
adenoma-carcinoma sequence of the large bowel. Virchows Arch.
426:149–154. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosivatz E, Becker I, Bamba M, Schott C,
Diebold J, Mayr D, Höfler H and Becker KF: Neoexpression of
N-cadherin in E-cadherin positive colon cancers. Int J Cancer.
111:711–719. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fanali C, Lucchetti D, Farina M, Corbi M,
Cufino V, Cittadini A and Sgambato A: Cancer stem cells in
colorectal cancer from pathogenesis to therapy: Controversies and
perspectives. World J Gastroenterol. 20:923–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong I, Hong SW, Chang YG, Lee WY, Lee B,
Kang YK, Kim YS, Paik IW and Lee H: Expression of the cancer stem
cell markers CD44 and CD133 in colorectal cancer: An
immunohistochemical staining analysis. Ann Coloproctol. 31:84–91.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cherciu I, Bărbălan A, Pirici D,
Mărgăritescu C and Săftoiu A: Stem cells, colorectal cancer and
cancer stem cell markers correlations. Curr Health Sci J.
40:153–161. 2014.PubMed/NCBI
|
|
23
|
Hamilton SR, Bosman FT and Boffetta P:
Carcinoma of the colon and rectumWHO Classification of Tumours of
the Digestive System. 4th. Bosman FT, Carneiro F, Hruban RH and
Theise ND: IARC Press; Lyon: pp. 132–146. 2010
|
|
24
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging manual. 7th. Springer;
New York, NY: pp. 237–246. 2010
|
|
25
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: CD133 expression is an independent prognostic marker for
low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan F, Samuel S, Evans KW, Lu J, Xia L,
Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, et al: Overexpression of
snail induces epithelial-mesenchymal transition and a cancer stem
cell-like phenotype in human colorectal cancer cells. Cancer Med.
1:5–16. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Horst D, Scheel SK, Liebmann S, Neumann J,
Maatz S, Kirchner T and Jung A: The cancer stem cell marker CD133
has high prognostic impact but unknown functional relevance for the
metastasis of human colon cancer. J Pathol. 219:427–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Choi D, Lee HW, Hur KY, Kim JJ, Park GS,
Jang SH, Song YS, Jang KS and Paik SS: Cancer stem cell markers
CD133 and CD24 correlate with invasiveness and differentiation in
colorectal adenocarcinoma. World J Gastroenterol. 15:2258–2264.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huh JW, Kim HR, Kim YJ, Lee JH, Park YS,
Cho SH and Joo JK: Expression of standard CD44 in human colorectal
carcinoma: Association with prognosis. Pathol Int. 59:241–246.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zavrides HN, Zizi-Sermpetzoglou A,
Panousopoulos D, Athanasas G, Elemenoglou I and Peros G: Prognostic
evaluation of CD44 expression in correlation with bcl-2 and p53 in
colorectal cancer. Folia Histochem Cytobiol. 43:31–36.
2005.PubMed/NCBI
|
|
35
|
Zhou JY, Chen M, Ma L, Wang X, Chen YG and
Liu SL: Role of CD44high/CD133high HCT-116
cells in the tumorigenesis of colon cancer. Oncotarget.
7:7657–7666. 2016. View Article : Google Scholar : PubMed/NCBI
|
